Hebei Senlang Biotechnology

CAR-T cell therapy (private)

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
BCMACell therapy
Multiple Myeloma
Preclinical / Unstaged
CD7Cell therapy
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
SENL103Phase 1/2Multiple Myeloma in Relapse, Multiple Myeloma Refractory
Est. primary completion 2028-02-01 · NCT07421856 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.